The first Favipiravir-based drug in the world approved for the treatment of COVID-19
Research and development of medicines
Development and introduction in manufacture of innovative and reproduced synthetic and biotechnological Medicinal products "on a turn-key basis"
Investment activities
Investing in the development of innovative drugs; joint development of the projects of the ChemRar portfolio on partner terms; licensing and transfer of rights to the results of intellectual activity

«ChemRar» High-Tech center:

We develop and manufacture effective, safe and affordable medicines for the treatment of socially significant diseases and improvement of the quality of life:

• Using experience and global standards at all stages of creation of a novel medicine;

• Contributing to the development of the scientific and technological potential of the pharmaceutical industry in Russia;

• Applying our knowledge to search for optimal solutions for our partners.


Chromis, a joint venture of the Russian Direct Investment Fund (RDIF) and ChemRar Group, was rated by Rospatent among Russia’s TOP 100 Inventions for the second half of 2020 and was awarded a diploma for the development of a favipiravir-based formulation Avifavir® — the world's first medicine registered for COVID-19 treatment. In addition to ...

The high efficacy of Avifavir®, the first registered drug for the treatment of COVID-19, in clinical practice was recognized at the All-Russian Congress on Infectious Diseases. Last week saw the closing of the 13th All-Russian Congress on Infectious Diseases named after academician V.I. Pokrovsky “Infectious Diseases in the Modern World: Current ...

Indonesia registers Russian drug with proven clinical efficacy against coronavirus Avifavir was the first Favipiravir-based drug in the world approved for the treatment of coronavirus and the first drug registered in Russia to treat coronavirus Moscow, March 24, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) ...

Chromis (Russia), a joint venture of the ChemRar Group and the Russian Direct Investment Fund (RDIF), and its partner Viriom Inc., a San Diego CA-based biotech reported a summary of the multicenter, open-labeled, efficacy and safety study of Avifavir (favipiravir) in patients with COVID-19 at the Conference on Retroviruses and Opportunistic ...

all news
Do you want to be aware of pharmaceutical news?
Subscribe to the weekly newsletter.

    I agree to the processing of personal data. Privacy policy